SCHEMBL4247417

SCHEMBL4247417

NC(c1ccccc1-c1ccccc1C(=O)NCCc1ccccc1)S(=O)(=O)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
HPGD P15428 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
KDM1A O60341 1/20 0.48
MAOA P21397 1/20 0.48
LMNA P02545 2/20 0.47
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
TAAR1 Q96RJ0 1/20 0.45
CXCR3 P49682 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
THRB P10828 1/20 0.43
ALOX12 P18054 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245385 0.85 RAB9A (0.46) ALDH1A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL4236018 0.81 ALDH1A1 (0.50) ALDH1A1LMNANPC1RAB9AKMT2A
SCHEMBL4248643 0.81 CA1 (0.46) ALDH1A1LMNANPC1RAB9AMEN1
SCHEMBL2208953 0.79 KCNA5 (0.56) ALDH1A1HPGDSMN1; SMN2KDM1AMAOA
SCHEMBL4242916 0.76 CHRNB2 (0.46) ALDH1A1LMNARAB9AMEN1KMT2A
SCHEMBL4248727 0.74 ALDH1A1 (0.50) ALDH1A1LMNARAB9AMEN1KMT2A
SCHEMBL2211229 0.70 CYP19A1 (0.56) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4244514 0.69 HTT (0.55) SMN1; SMN2LMNANPC1RAB9ACA1
SCHEMBL17554167 0.69 ALDH1A1 (0.77) ALDH1A1HPGDSMN1; SMN2LMNANPC1
SCHEMBL28763268 0.69 NPC1 (0.66) ALDH1A1HPGDSMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 ALDH1A1 217/4885HPGD 3474/4885SMN1; SMN2 4349/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E ALDH1A1 213/4885HPGD 3445/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.